References / Additional Resources
Centers for Disease Control (CDC). HIV. Basic Statistics. July 1, 2020. Accessed September 9, 2020.
Westby M, Lewis M, Whitcomb J, et al. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol. 2006 May;80(10):4909-20. doi: 10.1128/JVI.80.10.4909-4920.2006.
Kinloch-De Loës S, Hirschel BJ, Hoen B, et al. A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med. 1995 Aug 17;333(7):408-13. doi: 10.1056/NEJM199508173330702.
Classification and diagnostic criteria for oral lesions in HIV infection. EC-Clearinghouse on Oral Problems Related to HIV Infection and WHO Collaborating Centre on Oral Manifestations of the Immunodeficiency Virus.J Oral Pathol Med. 1993 Aug;22(7):289-91.
Ramírez-Amador V, Ponce-De-León S, Sierra-Madero J, et al. Synchronous kinetics of CD4+ lymphocytes and viral load before the onset of oral candidosis and hairy leukoplakia in a cohort of Mexican HIV-infected patients. AIDS Res Hum Retroviruses. 2005 Dec;21(12):981-90. doi: 10.1089/aid.2005.21.981.
Vaseliu N, Carter AB, Kline NE, et al. Longitudinal study of the prevalence and prognostic implications of oral manifestations in romanian children infected with human immunodeficiency virus type 1. Pediatr Infect Dis J. 2005 Dec;24(12):1067-71.
Baccaglini L, Atkinson JC, Patton LL, et al. Management of oral lesions in HIV-positive patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Mar;103 Suppl:S50.e1-23. doi: 10.1016/j.tripleo.2006.11.002.
Kademani D, Glick M. Oral ulcerations in individuals infected with human immunodeficiency virus: clinical presentations, diagnosis, management, and relevance to disease progression. Quintessence Int. 1998 Aug;29(8):523-34.
Bhayat A, Yengopal V, Rudolph M. Predictive value of group I oral lesions for HIV infection. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010 May;109(5):720-3. doi: 10.1016/j.tripleo.2009.11.019. Epub 2010 Mar 29.
Thompson GR 3rd, Patel PK, Kirkpatrick WR, et al. Oropharyngeal candidiasis in the era of antiretroviral therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010 Apr;109(4):488-95. doi: 10.1016/j.tripleo.2009.11.026. Epub 2010 Feb 13.
Shugars DC, Slade GD, Patton LL, et al. Oral and systemic factors associated with increased levels of human immunodeficiency virus type 1 RNA in saliva. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000 Apr;89(4):432-40.
Miziara ID, Filho BC, Weber R. Oral lesions in Brazilian HIV-infected children undergoing HAART. Int J Pediatr Otorhinolaryngol. 2006 Jun;70(6):1089-96. Epub 2006 Jan 6. doi: 10.1016/j.ijporl.2005.11.010.
Lawn SD, Checkley A, Wansbrough-Jones MH. Acute bilateral parotitis caused by Mycobacterium scrofulaceum: immune reconstitution disease in a patient with AIDS. Sex Transm Infect. 2005 Dec;81(6):517-8. doi: 10.1136/sti.2005.014993.
Centers for Disease Control and Prevention and Association of Public Health Laboratories. Laboratory Testing for the Diagnosis of HIV Infection: Updated Recommendations. Published June 27, 2014. Accessed September 9, 2020.
U.S. Department of Health and Human Services. AIDs Info. FDA-Approved HIV Medicines. July 22, 2020. Accessed September 9, 2020.
Siegel JD, Rhinehart E, Jackson M, et al. 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings. Am J Infect Control. 2007 Dec;35(10 Suppl 2):S65-164. doi: 10.1016/j.ajic.2007.10.007.
Do AN, Ciesielski CA, Metler RP, et al. Occupationally acquired human immunodeficiency virus (HIV) infection: national case surveillance data during 20 years of the HIV epidemic in the United States. Infect Control Hosp Epidemiol. 2003 Feb;24(2):86-96. doi: 10.1086/502178.
Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med. 1997 Nov 20;337(21):1485-90. doi: 10.1056/NEJM199711203372101.
Kuhar DT, Henderson DK, Struble KA, et al. Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Infect Control Hosp Epidemiol. 2013 Sep;34(9):875-92. doi: 10.1086/672271.
Henderson DK, Fahey BJ, Willy M, et al. Risk for occupational transmission of human immunodeficiency virus type 1 (HIV-1) associated with clinical exposures. A prospective evaluation. Ann Intern Med. 1990 Nov 15;113(10):740-6.
Ippolito G, Puro V, De Carli G. The risk of occupational human immunodeficiency virus infection in health care workers. Italian Multicenter Study. The Italian Study Group on Occupational Risk of HIV infection. Arch Intern Med. 1993 Jun 28;153(12):1451-8.
Henderson DK, Dembry L, Fishman NO, et al. SHEA guideline for management of healthcare workers who are infected with hepatitis B virus, hepatitis C virus, and/or human immunodeficiency virus. Infect Control Hosp Epidemiol. 2010 Mar;31(3):203-32. doi: 10.1086/650298.
Crossley ML. An investigation of dentists' knowledge, attitudes and practices towards HIV+ and patients with other blood-borne viruses in South Cheshire, UK. Br Dent J. 2004 Jun 26;196(12):749-54, quiz 780. doi: 10.1038/sj.bdj.4811382.
No Additional Resources Available